Last reviewed · How we verify

Tevimbra (TISLELIZUMAB)

Beigene · FDA-approved approved Monoclonal antibody Quality 50/100

Tevimbra blocks the PD-1 receptor, allowing the immune system to recognize and attack cancer cells.

Tevimbra (tislelizumab) is a monoclonal antibody developed by Beigene that targets the PD-1 receptor, a protein that helps cancer cells evade the immune system. It works by blocking the PD-1 receptor, allowing the immune system to recognize and attack cancer cells. Tevimbra is approved to treat various types of esophageal and gastric cancers, including unresectable or metastatic esophageal squamous cell carcinoma and unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma. Tevimbra is a patented product owned by Beigene, with no generic manufacturers listed. Key safety considerations include potential immune-mediated adverse reactions.

At a glance

Generic nameTISLELIZUMAB
SponsorBeigene
Drug classProgrammed Death Receptor-1 Blocking Antibody [EPC]
TargetPd-1
ModalityMonoclonal antibody
Therapeutic areaOncology
PhaseFDA-approved
First approval2025
Annual revenue900

Mechanism of action

Binding of the PD-1 ligands PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Tislelizumab-jsgr binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. Tislelizumab-jsgr decreased tumor growth in xenograft models and a human PD-1 transgenic mouse model.

Approved indications

Common side effects

Key clinical trials

Patents

PatentExpiryType
Biologic Exclusivity

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results
FDA Orange BookPatents + exclusivity
SEC EDGARRevenue + earnings

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: